JP2019518798A - リポヌクレオチドに基づくardsの治療 - Google Patents

リポヌクレオチドに基づくardsの治療 Download PDF

Info

Publication number
JP2019518798A
JP2019518798A JP2019519626A JP2019519626A JP2019518798A JP 2019518798 A JP2019518798 A JP 2019518798A JP 2019519626 A JP2019519626 A JP 2019519626A JP 2019519626 A JP2019519626 A JP 2019519626A JP 2019518798 A JP2019518798 A JP 2019518798A
Authority
JP
Japan
Prior art keywords
cdp
composition
choline
ards
dag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019519626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518798A5 (enExample
Inventor
イアン・クリストファー・デイビス
Original Assignee
オハイオ・ステイト・イノベーション・ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オハイオ・ステイト・イノベーション・ファウンデーション filed Critical オハイオ・ステイト・イノベーション・ファウンデーション
Publication of JP2019518798A publication Critical patent/JP2019518798A/ja
Publication of JP2019518798A5 publication Critical patent/JP2019518798A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019519626A 2016-06-27 2017-06-27 リポヌクレオチドに基づくardsの治療 Pending JP2019518798A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662355096P 2016-06-27 2016-06-27
US62/355,096 2016-06-27
PCT/US2017/039545 WO2018005527A1 (en) 2016-06-27 2017-06-27 Liponucleotide-based therapy for ards

Publications (2)

Publication Number Publication Date
JP2019518798A true JP2019518798A (ja) 2019-07-04
JP2019518798A5 JP2019518798A5 (enExample) 2020-08-06

Family

ID=60786443

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019519626A Pending JP2019518798A (ja) 2016-06-27 2017-06-27 リポヌクレオチドに基づくardsの治療

Country Status (9)

Country Link
US (2) US10874684B2 (enExample)
EP (2) EP4292651A3 (enExample)
JP (1) JP2019518798A (enExample)
KR (1) KR20190022682A (enExample)
CN (1) CN109475554A (enExample)
AU (1) AU2017289278A1 (enExample)
CA (1) CA3029005A1 (enExample)
SG (1) SG11201811595SA (enExample)
WO (1) WO2018005527A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811595SA (en) * 2016-06-27 2019-01-30 Ohio State Innovation Foundation Liponucleotide-based therapy for ards
US11154621B2 (en) 2017-06-27 2021-10-26 Ohio State Innovation Foundation Liponucleotide-based therapy for COPD
JP2023519958A (ja) * 2020-03-31 2023-05-15 ディフュージョン・ファーマシューティカルズ・エルエルシー ウイルス及び細菌誘導性呼吸器疾患の治療のための拡散増強化合物の使用
EP4142709A4 (en) * 2020-05-01 2024-05-22 Irazu Bio Method for treating respiratory viral infections comprising administration of fatty acid compositions
WO2023173043A1 (en) * 2022-03-11 2023-09-14 Arizona Board Of Regents On Behalf Of Arizona State University Pegylated serp-1 protein treatment improves outcomes after sars-cov-2 infection
WO2023177995A2 (en) * 2022-03-18 2023-09-21 Ohio State Innovation Foundation Cdp-choline a host-directed therapeutic for disease caused by sars cov-2 infection

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386078A (en) * 1980-03-03 1983-05-31 The Ohio State University Research Foundation Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation
JPH02500372A (ja) * 1987-10-28 1990-02-08 プロ‐ニューロン,インコーポレーテッド アシル化ウリジンおよびシチジンならびにその使用
US20030181353A1 (en) * 1998-08-03 2003-09-25 Nyce Jonathan W. Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia
JP2005513023A (ja) * 2001-11-21 2005-05-12 ダンマークス・ヨードブルースフォースクニング 抗炎症剤としてのモノ−およびジアシルグリセロールのグリコシドの使用
JP2008542280A (ja) * 2005-05-23 2008-11-27 マサチューセッツ・インスティチュート・オブ・テクノロジー Pufa及び/又はウリジンを含有する組成物及びそれを使用した方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
CN101066276A (zh) * 1994-07-01 2007-11-07 威尔斯塔特医疗公司 用于治疗全身性炎症和炎性肝炎的嘧啶核苷酸前体
US6825174B2 (en) * 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US20040049022A1 (en) * 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
EP1408987B1 (en) * 2001-07-13 2013-04-10 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
EA012138B1 (ru) * 2004-11-17 2009-08-28 Йиссум Рисерч Дивелопмент Компани Оф Дзе Хебрю Юниверсити Оф Иерусалим Применение конъюгатов липидов при лечении заболеваний
CN101495490B (zh) * 2005-05-23 2018-05-08 麻省理工学院 含有多不饱和脂肪酸和/或尿苷的组合物及其使用方法
SG11201811595SA (en) * 2016-06-27 2019-01-30 Ohio State Innovation Foundation Liponucleotide-based therapy for ards
US11154621B2 (en) * 2017-06-27 2021-10-26 Ohio State Innovation Foundation Liponucleotide-based therapy for COPD
US11850283B2 (en) * 2017-06-27 2023-12-26 Ohio State Innovation Foundation Liponucleotide-based therapy for asthma

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386078A (en) * 1980-03-03 1983-05-31 The Ohio State University Research Foundation Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation
JPH02500372A (ja) * 1987-10-28 1990-02-08 プロ‐ニューロン,インコーポレーテッド アシル化ウリジンおよびシチジンならびにその使用
US20030181353A1 (en) * 1998-08-03 2003-09-25 Nyce Jonathan W. Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia
JP2005513023A (ja) * 2001-11-21 2005-05-12 ダンマークス・ヨードブルースフォースクニング 抗炎症剤としてのモノ−およびジアシルグリセロールのグリコシドの使用
JP2008542280A (ja) * 2005-05-23 2008-11-27 マサチューセッツ・インスティチュート・オブ・テクノロジー Pufa及び/又はウリジンを含有する組成物及びそれを使用した方法

Also Published As

Publication number Publication date
CN109475554A (zh) 2019-03-15
CA3029005A1 (en) 2018-01-04
EP3474853A4 (en) 2020-02-19
AU2017289278A1 (en) 2019-01-17
US20210069225A1 (en) 2021-03-11
WO2018005527A1 (en) 2018-01-04
EP4292651A2 (en) 2023-12-20
SG11201811595SA (en) 2019-01-30
US10874684B2 (en) 2020-12-29
EP3474853A1 (en) 2019-05-01
KR20190022682A (ko) 2019-03-06
EP4292651A3 (en) 2024-03-13
US20190134074A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
US10874684B2 (en) Liponucleotide-based therapy for ARDS
JP6824434B2 (ja) ネココロナウイルス感染を処置する方法
US20240245646A1 (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
ES2988617T3 (es) Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales
US20170354711A1 (en) High density lipoprotein nanoparticles for inflammation
JP2001520656A (ja) 抗腫瘍剤としてのホルボールエステル類
JP2016121188A (ja) 肝細胞がんの予防及び/又は治療のための医薬
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
JP2013510838A (ja) 微生物感染症の治療
EP3645009A1 (en) Liponucleotide-based therapy for copd
TW202203946A (zh) 用於人或動物之慢性或急性之病毒感染症及/或敗血症之預防或治療的組成物
HK40003888A (en) Liponucleotide-based therapy for ards
JP2004504346A (ja) 骨転移の治療におけるリン酸エストラムスチンの使用
EP4104825A1 (en) Pharmaceutical composition for inhibiting inflammatory response comprising hydroxyurea
US20250170246A1 (en) Cdp-choline a host-directed therapeutic for disease caused by sars cov-2 infection
TW202019440A (zh) 用於治療癌症之組合療法
JP2017527567A5 (enExample)
CN112533604A (zh) 用于治疗癌症的组合疗法
JP6959049B2 (ja) 新規低アルブミン血症改善薬
JP2019503344A (ja) 細菌感染を治療する新規方法
CN1739543A (zh) 抗肿瘤化合物nobilisideA单乙酰化物脂质体静脉注射液及其制法
WO2022121884A1 (zh) 伊维菌素及其类似物在皮肤相关疾病治疗中的应用
HK40041872A (en) Method for preventing and/or treating aging-associated cognitive impairment
WO2013008681A1 (ja) 線維症予防又は治療用医薬組成物
JP2004143068A (ja) インフルエンザ脳炎・脳症の予防及び/又は治療のための医薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210706

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220208